Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 537
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Chairperson
Scott A. Armstrong
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Cancer genomics: A translational future
Elaine R. Mardis
Washington University School Of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Targeting epigenomic dependencies in cancer
James E. Bradner
Novartis, Cambridge, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Genome editing using CRISPR-Cas systems
Feng Zhang
Massachusetts Institute of Technology, Cambridge, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
T cell recognition of human cancer
Ton Schumacher
Netherlands Cancer Inst., Amsterdam, Netherlands
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Stem cells and cancer
Elaine Fuchs
Howard Hughes Medical Institute/Rockefeller University, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Addressing the Mechanisms of Resistance and Lack of Response in Cancer Immunotherapy
The tumor immunity continuum as a framework for rational combinations
Priti S Hegde
Genentech, South San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:15 PM
Addressing the Mechanisms of Resistance and Lack of Response in Cancer Immunotherapy
Combinations using checkpoint blockade as one means to address resistance
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:15 PM
Addressing the Mechanisms of Resistance and Lack of Response in Cancer Immunotherapy
In vivo discovery of novel targets for cancer immunotherapy
Kai Wucherpfennig
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2016 on April 18, 2016 10:30 AM-12:15 PM
Antibodies and Nanoparticles for Targeted Radiotherapy to Cancer
Molecular radiotherapy: Intracellular targets and delivery
Katherine A Vallis
Univ. of Oxford, Oxford, United Kingdom
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Antibodies and Nanoparticles for Targeted Radiotherapy to Cancer
Nanotechnology In Radiation Oncology
Andrew Z. Wang
University of North Carolina at Chapel Hill, Durham, NC, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Antibodies and Nanoparticles for Targeted Radiotherapy to Cancer
Conventional and Pretargeted Radioimmunotherapy for B Cell Lymphomas
Damian Green
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Antibodies and Nanoparticles for Targeted Radiotherapy to Cancer
AntibodiesTargeted to Radiation Inducible Antigens in Cancer
Dennis E. Hallahan
Washington University School of Medicine, St. Louis, MO, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Cancer Metabolism and Immunometabolism: Metabolic Decisions in Oncology
Understanding and exploiting metabolic flexibility in cancer cells
Christian Metallo
UCSD, La Jolla, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Cancer Metabolism and Immunometabolism: Metabolic Decisions in Oncology
Metabolic reprogramming mechanisms
Heather R. Christofk
UCLA School of Medicine, Institute for Molecular Medicine, Los Angeles, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Cancer Metabolism and Immunometabolism: Metabolic Decisions in Oncology
Mapping metabolicdrivers of cancer using chemoproteomic and metabolomic platforms
Daniel Nomura
University of California, Berkeley, Berkeley, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Cancer Metabolism and Immunometabolism: Metabolic Decisions in Oncology
Innate immune: Microbiome interactions in cachexia
Janelle Ayres
Salk Institute for Biological Studies, La Jolla, CA, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
Microbiome and Cancer Immunotherapy
Cancer as a disease of the symbiont/metaorganism
Giorgio Trinchieri
NCI-Frederick, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 16, 2016 8:00 AM-10:00 AM
<< first | < prev page: of 22 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 19 20 21 22 presentations: 1 to 25 of 537